Big Pharma earned gold stars in 2014, as the industry's top drugmakers did more to get their meds to patients in the world's poorest countries. But despite recent progress, companies still have room to grow in R&D and distribution, the Index notes.
In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.
Novo Nordisk is investing around DKK 750 million ($130 million) in new laboratories at the firm's R&D campus in Måløv, Denmark. Construction is already underway for the new facility, dubbed Diabetes Research House, which Novo Nordisk says will...
Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next year, the Danish drugmaker said it's expecting growth in the high single digits.
Novo Nordisk is sounding a more cautious tone on Tresiba, its once-rejected new insulin. After hinting at an accelerated trip back to the FDA for the long-acting diabetes treatment, the Danish drugmaker now says it could be another few years...
Denmark’s Novo Nordisk, the world’s largest maker of insulin, said that it expects high single-digit sales growth and around 10% operating profit growth in 2015, as it reported a rise in third-quarter net profit.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):